UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) December 20, 2024

 

ARTELO BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

333-199213

 

33-1220924

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

505 Lomas Santa Fe, Suite 160  

Solana Beach, CA USA

 

92075 

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (858925-7049

 

___________________________________________

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

ARTL

 

The Nasdaq Stock Market, LLC

 

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

We held our Annual Meeting of Stockholders (“Annual Meeting”) on December 20, 2024. Of the 3,227,700 shares of our common stock outstanding and entitled to vote as of December 4, 2024, 1,319,986 or 40.9% of such shares were represented, either by attending the Annual Meeting or by proxy, constituting a quorum under our bylaws. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below.

 

1.  

Election of Directors. The following nominees were re-elected by the holders of our common stock to serve as directors to hold office until our 2027 annual meeting of stockholders and until their successors have been duly elected and qualified:

 

Class I Nominees

 

Nominee

For

Against

Abstain

Broker Non Vote

Steven Kelly

442,956

64,966

11,497

800,567

R. Martin Emanuele, Ph.D.

461,960

45,962

11,497

800,567

 

 

2. 

Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Malone Bailey LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting:

  

For

 

Against

 

Abstain

1,258,378

 

57,083

 

4,525

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ARTELO BIOSCIENCES, INC.

 

 

 

/s/ Gregory D. Gorgas

 

Gregory D. Gorgas

 

President & Chief Executive Officer

 

 

 

Date: December 20, 2024

 

 

 

3